VentureBeat November 8, 2021
Kyle Wiggers

Google’s parent company Alphabet last week launched a subsidiary focused on AI-powered drug discovery called Isomorphic Labs. Helmed by Demis Hassabis, the cofounder of DeepMind, Isomorphic will use AI to identify disease treatments that have thus far eluded researchers, according to a blog post.

“Isomorphic Labs [is] a commercial venture with the mission to reimagine the entire drug discovery process from the ground up with an AI-first approach,” Hassabis wrote. “[Ultimately, we hope] to model and understand some of the fundamental mechanisms of life … There may be a common underlying structure between biology and information science — an isomorphic mapping between the two — hence the name of the company.”

The launch of Isomorphic underlines the pressure on corporate-backed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Technology
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Alphabet shares jump 14% on earnings beat, first-ever dividend
Microsoft: Unlocking AI Benefits Will Require Cultural Changes for Enterprises
Zephyr AI Raises $111 Million in Series A Financing
Chatbot answers are all made up. This new tool helps you figure out which ones to trust.

Share This Article